Leqembi Receives Positive Public Reimbursement Recommendation in Canada BioArctic announced that CDA-AMC has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for el...
Takeaways: The positive reimbursement recommendation from Canada’s drug agency moves Leqembi closer to public funding for early Alzheimer’s disease, which can significantly expand the ...
Takeaways: Grey Matter’s focused ultrasound platform aims to offer a non‑invasive option for people whose depression hasn’t improved with medications or therapy, by precisely stimulating deep brain ci...
Takeaways: If governments adopt the CDA-AMC recommendation, Ubrelvy could gain public coverage and expand AbbVie’s migraine footprint in Canada, creating a stronger commercial path for...
Takeaways: Leqembi’s positive reimbursement step in Canada is a meaningful commercial win because it could unlock public coverage for the first disease-modifying Alzheimer’s therapy in the count...
Takeaways: Brain Canada is using these Platform Support Grants to build durable infrastructure in Western Canada that can change how brain and mental health research is done, not just fund singl...
Takeaways: Kisunla adds a new money‑maker for Lilly in Canada, but real sales will depend on how fast the system can diagnose patients early and pay for the drug. Because testing and speci...
